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Abstract  
Importance: Teledermatology is a topical clinical approach being trialled in Australia and 
overseas (1). With a majority of dermatologists residing in metropolitan areas, 
teledermatology provides an apparent low cost and convenient means of access for 
individuals living outside these areas (1, 2). It is important that any proposed new addition to 
a healthcare system is assessed on the ground of economic cost and effectiveness. 
Objective: To summarise and evaluate the current economic evidence comparing store-and-
forward teledermatology (S&FTD) with conventional face-to-face (FTF) care. 
Evidence Review: Search terms with appropriate amendments were used to return S&FTD 
articles that included economic analysis. Six databases were searched; title, abstract and full 
text reviews were conducted by two researchers. References of all unique returned articles 
were searched by hand. (3) 
Findings: Eleven articles were selected for inclusion; consisting of once cost-analysis, five 
cost-minimisation analyses, three cost-effectiveness analyses and two cost-utility analyses. 
The Consolidated Health Economic Evaluation Reporting Standards checklist was used to 
evaluate quality, scores ranged from 7 to 21 out of a possible 24 points, with a median score 
of 17.   
Conclusions and Relevance: Current evidence is sparse, but suggests that S&FTD can be 
cost-effective. It appears to be cost-effective when it is used as a triage mechanism to reduce 
FTF appointment requirements. The cost-effectiveness of S&FTD increases when patients 
are required to travel further distances to access dermatology services. Further economic 
research is required for the emerging S&FTD which uses dermatoscopes in combination with 
smartphone applications, and around the possibility and consequences of patients self-
capturing and transmitting images. 
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Background 
Teledermatology is an area of healthcare described by the fusion of dermatological care and 
telehealth. It is attractive because it optimises current processes and results in a more efficient 
use of resources (4). It uses either video conference or store-and-forward technology to 
increase population access to dermatologist specialists (2, 5). Store-and-forward 
teledermatology (S&FTD) involves images of lesions or skin sections being captured and 
transmitted electronically to a dermatologist, generally accompanied by a relevant patient 
history. The dermatologist reviews the images and relevant history and replies with a 
diagnostic opinion and suggested action plan. There are many models of care for S&FTD 
involving different individuals collecting the images and health information such as nurses, 
general practitioners (GPs), or patients (6). One of the primary uses being explored is using 
S&FTD as a method of referral between GPs and dermatologists instead of the conventional 
written referral method (7). Teledermatology enables dermatologists to triage cases more 
effectively, or refer patients back to the GPs for management. It is widely accepted that 
dermatologists are more effective at diagnosing dermatological conditions than GPs, 
therefore it follows that GPs prefer to refer dermatological cases that they are hesitant or 
suspicious about (4, 8). The teledermatology feedback or refer-back process has the potential 
to shorten the waiting lists for specialists, and increase convenience for patients whilst 
ensuring that patients are receiving optimal care (9-11).   
Teledermatology is an ever expanding area in Australia and overseas (1). With a large 
majority of dermatologists residing in metropolitan areas, teledermatology provides an 
apparent low cost and convenient means of access for individuals living outside these areas 
(1, 2). It is important that any proposed new addition to a healthcare system is assessed on the 
ground of economic cost and effectiveness. The economic effectiveness of interventions is 
calculated by applying an economic value to each intervention and an effectiveness or utility 
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measure to quantify the outcome. The economic cost is then weighted based on the efficacy 
or utility value of the outcome. There are four types of economic evaluation relevant to this 
review; cost-analysis (CA), cost-minimisation analysis (CMA), cost-effectiveness analysis 
(CEA), and cost-utility analysis (CUA). CA and CMA provide findings in terms of difference 
in costs. CA presents only financial values, while a well-designed CMA addresses the 
equivalent efficacy between the interventions to justify presenting results in cost terms only. 
If this is not justified appropriately it is possible that CMA may miss key comparator 
information between interventions (3). CEA and CUA weight the cost findings in terms of 
the intervention outcome (either in terms of clinical effectiveness or a pre-defined utility 
measure such as the quality-adjusted life year, QALY) (3, 12). Each of these methods is only 
as accurate as the information used to estimate the cost, efficacy, or utility outcomes (3). This 
review aims to synthesise their results and assess the current level of evidence for 
teledermatology cost-effectiveness.   
Objectives 
To summarise and evaluate the current economic evidence comparing store-and-forward 
teledermatology (S&FTD) with conventional face-to-face (FTF) care.  
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Method  
Search strategy  
This review follows the methods described in a published protocol (PROSPERO 
2015:CRD42015014295). Studies were included if (i) they related to any population 
requiring dermatological care; (ii) they included a store-and-forward teledermatology 
intervention, regardless of the device or individual used to capture the images; (iii) the 
intervention was compared to conventional care defined as a FTF consultation; and (iv) the 
outcome is expressed in terms of any kind of economic analysis. No limits were put on 
publication date, but only full-text journal articles available in English were included.  
 
Search terms with appropriate amendments (dependent on MESH terms) used to search 
EMBASE, EconLit, PubMed, MedLine, Cochrane, and CINAHL were (cost or economic) 
AND (teledermatology or teledermoscopy or telederm*), AND store-and-forward. Google 
and Google Scholar were also searched to identify any other unique literature not returned 
through the above databases, and the references of all returned articles were searched by 
hand.  
 
Article selection 
After duplicates were removed, titles and abstracts were screened for eligibility. The 
remaining articles were then read in full text to confirm eligibility. Eligible articles were 
those that described any cost analysis performed that compared conventional care and 
teledermatology as per the inclusion criteria stated previously. The primary search was 
conducted by one researcher (CS). Abstracts were reviewed by two researchers (CS and JW), 
with any disagreement discussed to reach consensus.  During the final stage of full text 
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review a third researcher (RM) read the articles that met the criteria to confirm their 
inclusion.  
Data extraction and analysis  
Data including study design, economic content and S&FTD methods used, were extracted 
using a standard form based on the CASP (Critical Appraisal Skills Programme) for 
economic evaluation and the Consolidated Health Economics Evaluation Reporting 
Standards (CHEERS) checklist (3, 13). As few restrictions were placed on the economic or 
S&FTD aspects of the literature included the identified studies varied widely, therefore 
numerous data points were extracted in order to effectively contrast the studies.  The 
CHEERS checklist was used to assess the quality of each article by assigning them a value 
out of 24, with higher scores indicating more complete reporting against the 24-items (3). 
Economic principles such as currency, discounting, time horizon, effectiveness measures, 
choice of outcome, assumptions, and model choice are all included (3). The checklist also 
includes items that would be applicable to other study types such as population information, 
and characterisation of uncertainty, analytical methods, parameters and heterogeneity (3).  
Meta-analysis was not completed on the selected studies due to the inappropriateness of 
directly comparing economic outcomes between varying countries and health systems, and 
the lack of sufficient studies within one system. 
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Results 
Study Selection 
The study extraction and selected results are listed in Figure 1. Eleven of the 59 full-text 
articles screened according to the PRISMA guidelines remained for inclusion (14).  
 
Study characteristics  
All included studies examined teledermatology as a means of optimising referrals to 
dermatologists. Ten of the eleven studies involved GPs identifying patients as requiring a 
dermatologist referral (4, 7-11, 15-18). Teledermatology was compared to the conventional 
model of written referral to a dermatologist where all patients attend a FTF appointment, the 
urgency of which was determined by the referral letter written by the GP (4, 7-11, 15-18). 
Dermatologists reviewed the images and responded by either scheduling a face-to-face 
appointment, giving guidance for GP management of the condition, or concluding that no 
action was required (1, 4, 7-11, 15-18). The remaining study involved psoriasis patients 
sending information directly to their dermatologist to decide if a FTF appointment was 
required (1). Six studies showed that teledermatology was able to reduce the number of 
patients required to attend FTF consultations with a dermatologist by 39-88% (Table 1) (9-
11, 17, 18).  This in turn reduced the waiting time for those patients who did require an 
appointment (8-11, 17, 18).  
 
Study quality  
. Overall evidence quality was appraised for each article by using an abridged version of the 
rating system published by the Oxford Centre (Table 2). The CHEERS checklist was used to 
evaluate the adherence to best practice reporting, quality scores ranged from 7 to 21 out of a 
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possible 24 points, with a median score of 17 (Table 1) (3).  The CHEERS score represents 
how well the authors adhered to best practice when reporting their study.  Two studies (Datta 
and Eminovic) outlined a time horizon, and only one (Eminovic) discussed a discounting 
method for their study (4, 15). The lower scores were due to a failure to report or discuss 
relevant economic principles or justify the choice of analysis (3). For S&FTD the most 
relevant principles that were not included were time horizons (study lengths and appropriate 
financial conversions), financial referencing (all figures should be cited), and the choice of 
analysis should always be justified whether with efficacy or economic data explaining all 
assumptions. It is reasonable to expect a high quality analysis to address each of the 24 points 
in the checklist, even if only to explain why that item was not included or calculated (3).  
 
Economic Findings  
The majority of the studies (82%), with the exception of Eminović and Datta concluded that 
teledermatology using store-and-forward technology was cost-effective (1, 7-11, 16-18). 
These conclusions are presented in Table 2. Three of the eleven studies used CEA and 
expressed their outcome effect in terms of days to “initial intervention”, where “initial 
intervention” was categorised as either initial FTF appointment (for patients requiring a FTF 
consult), or diagnostic feedback being received by GP from dermatologist (if patient not 
required to attend FTF) (Table 2) (7, 9, 16). Two papers applied a CUA and measured 
QALYs and cost in their studies, and outcomes were expressed as incremental cost per 
QALY gained (1, 4).  QALYs are a robust preference-based measure for utility that is 
commonly used to value health interventions (19). QALYs were calculated using the time 
trade-off method by Datta, and the Dermatology Life Quality Index (DLQI) based on the 
QALY model score by Parsi (1, 4). Datta found no difference between the QALY outcome 
for S&FTD and written referral, as a result the findings were described as a CMA (4).  
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The countries in which the studies were conducted varied broadly, with the highest number of 
studies (36%) conducted in the United States of America (USA) (Table 1). Of the eleven 
studies, eight (73%) reported results from the perspective of their national health system 
(NHS) or, the national department for defence or Department of Veteran Affairs (DVA) who 
service a smaller subset of the population (Table 2) (4, 7, 8, 10, 11, 16-18). NHS systems and 
DVA systems differ between country in terms of delivery, governance, and what is covered. 
Eminovic, Datta, and Parsi described their analyses as being from a societal perspective (1, 4, 
15). Parsi characterised societal perspective as the cumulative costs incurred by the health 
institutions, the patient (including productivity, travel and time) and the government (1). 
Datta and Eminovic also included travel costs, out-of-pocket expenses, and productivity 
losses (4, 15).  
 
There were three outcomes used to describe the difference between teledermatology and 
conventional care. Outcomes were expressed by the number of referrals, time in days to the 
“initial intervention” (as defined previously), or in QALYs (1, 4, 7, 9, 10, 16). Sensitivity 
analysis was performed in four studies, although calculation approaches varied (1, 7, 9, 15). 
The variable that was tested for sensitivity varied (Table 2). Parsi calculated the sensitivity of 
the reported travel time by specifying a plausible range from the literature and performing a 
one-way analysis (1). Whited, Eminovic, and Moreno-Ramirez performed one-way 
sensitivity analysis to assess the effect of a variation in travel requirements or the number of 
avoided face-to-face appointments on the cost-effectiveness of teledermatology, the findings 
were statistically significant (Table 2) (7, 9, 15). It was also demonstrated that a decrease in 
patient time requirements while undertaking teledermatology, or an increased travel 
requirements, increased the cost-effectiveness of S&FTD (1, 15, 16). Cost-effectiveness was 
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still maintained in the study by Moreno-Ramirez and colleagues even when the percentage of 
avoided FTF appointments observed in the study was assumed to reduce by half (9).  
 
Clinical characteristics  
The teledermatology methods and types of technology utilised in the studies varied.  
Differences included the skin condition, type of camera (digital camera or dermatoscope), 
forwarding method, who captured the image, and whether or not the system was costed in the 
analysis (see Table 3). The individual capturing the images, device, and transfer method were 
not standardised between studies. All studies used either proprietary software (websites, 
encrypted email, and server) or their NHS intranet to transfer the images. All teledermatology 
images were reviewed by a dermatologist together with the relevant clinical information. The 
industry gold standard for confirmation of dermatology diagnosis is histopathology (carried 
out by two studies) (9, 16). However two other studies acquired confirmation by having a 
second dermatologist review either all referrals or a subset of the referrals (1 in 10 for 
Livingstone) (10, 18).  
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Discussion 
This review has identified a small but growing body of evidence evaluating the cost-
effectiveness of S&FTD. By maintaining broad inclusion criteria, the review provides a 
comprehensive summary of the economic literature. Majority of the articles identified 
S&FTD as a clinically and economically effective model for referring patients to 
dermatologists (4, 7-11, 15-18), although the quality of this evidence is limited. The 
inconsistent results depending on the study context, and limitations in methodological quality 
of several studies mean that currently, only a weak recommendation for the cost-effectiveness 
of Teledermatology can be made (recommendation level 2A) (20). The final reported 
outcome depended on a range of factors, including the economic analysis method, the 
analysis perspective, and the sensitivity analysis performed. Effectiveness was primarily 
demonstrated by quantifying the number of unnecessary FTF dermatologist appointments 
prevented (8-11, 17, 18). Three articles recognised that cost savings were greater for patients 
located a further distance from a dermatology service due to the cost of travel (1, 15, 16).  
 
Analysis Perspective  
The studies retrieved present a narrow perspective of the cost of S&FTD due to the fact that 
most of them are from an NHS perspective. The NHS perspective (demonstrated by 73% of 
studies) only includes costs which would be incurred by the NHS (7-11, 16, 17). It does not 
take into account costs that may be incurred or spared for the patient or other parties such as 
travel time, productivity or wage loss, accommodation costs, or co-payments (3). While this 
information is good for policy makers it does not provide a full picture of the overall costs or 
cost savings of implementing S&FTD. Three of the studies considered additional societal 
costs in their analysis which gives a broader cost estimation by taking into account financial 
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costs for the NHS, and the patient (both direct costs and productivity/wage loss) (1, 4, 15). 
Similar to the other studies which performed their analysis from the perspective of the health 
system, two out of the three found S&FTD to be cost-effective (1, 4). However, in contrast, 
the third provided circumstances under which their analysis would show cost-effectiveness 
(15). Given that S&FTD offers the potential for reduced travel and increased convenience to 
the patient it may be more appropriate to present findings from a societal perspective in order 
to capture these gains more holistically.  
 
Sensitivity Analysis 
The extent to which findings were sensitive to assumptions made in the analyses were tested 
during analyses by most studies, generally only using one-way sensitivity analyses rather 
than more technically robust  approaches such as probabilistic sensitivity analysis. 
Nevertheless,   overall it can be concluded that while most studies show S&FTD to be cost-
effective, the extent of cost-effectiveness is affected by the travel requirements of patients 
and the number of FTF consultations it prevents. These two factors will be of particular 
relevance in areas where large geographical distances have to be overcome such as Australia. 
Thus, S&FTD may provide particularly good value for money, as well as benefits in terms of 
equity of access, in areas challenged by geographical remoteness. 
 
Analysis Method 
This review has shown that there is currently very limited economic evidence relating to the 
cost-effectiveness of S&FTD. The evidence available is derived primarily from CMA. This is 
due to the fact that economic analysis of the S&FTD services have been carried out after 
services were initialised through the NHS or DVA. It may also be due to challenges in 
collecting meaningful clinical indicators of effectiveness that are sensitive to change, 
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especially where the aim of S&FTD may relate to the identification or management of low-
incidence conditions (such as melanoma). One study evaluated outcomes and concluded no 
significant change in QALYs between teledermatology and the conventional referral model, 
the authors chose to present their results in a CMA format based on the statistical significance 
(4).  This change of method from a CUA to a CMA was argued by the authors to be 
appropriate given that the use of a CMA was justified. However, there is an economic 
literature arguing that even when outcomes are not statistically different, it is still relevant to 
perform a full cost-effectiveness or cost-utility analysis, since it is the ratio of incremental 
costs to benefits we are interested in, and this ratio can be significant, even if the outcomes 
alone are not (12).   
 
S&FTD in ten of the eleven studies was trialled as an addition to the current model of care, 
rather than a potential replacement for (4, 7-11, 15-18). Most studies posed that S&FTD be 
incorporated into the current model of care to optimise referrals and associated waiting lists 
to see dermatologists (8-11, 17, 18). In many countries, including but not limited to those 
included in this review, dermatologists are a scarce resource and waiting lists for 
consultations are long (11, 17). Although conventional care models attempt to triage high risk 
patients, this is hard to do from written referrals (8). S&FTD enables this triage to be done 
more effectively, therefore reducing waiting times for physical appointments for cases that 
require them (4, 7-11, 15-18).  
 
Teledermatology characteristics  
The S&FTD technology employed varied between studies (1, 4, 7-11, 15-18). Each system 
had different set up and maintenance cost. These costs were accounted for by six studies (1, 
7, 9, 10, 15, 16). The studies that did not include the set-up and maintenance cost either did 
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not address it at all, explained it as irrelevant (systems were already installed and in use by 
the NHS or DVA), or said the relatively low cost made it irrelevant. The studies that failed to 
address this cost may represent less robust findings than those that did. There is a large body 
of research emerging about using smart phone applications for S&FTD. The lack of current 
evidence around economic viability of smartphone applications for S&FTD means that there 
is currently inadequate literature assessing new S&FTD model of care and technology, 
reducing the generalisability of this review’s findings. Additionally a number of these studies 
(due to the year of the research and/or the implementation cost) utilised digital cameras to 
capture images. Dermatoscopes have become a standard instrument in dermatology, they are 
part of a routine FTF consultation, and have become inexpensive enough to incorporate into 
systems (10, 11, 17). The fast pace with which technology used for S&FTD progresses makes 
the contemporary evaluation of cost-effectiveness challenging. The lack of economic 
evaluation related to dermatoscopes and smartphones suggests an important avenue for 
further research.   
 
Limitations  
This review was comprehensive in its approach to identifying and summarising the economic 
literature on S&FTD, suggesting the approach generally provides good value for money. 
Nevertheless, the articles meeting criteria for inclusion had limitations. The CHEERS scores 
(Table 1) indicated that articles could have improved their studies by addressing more 
economic principles. The participant numbers varied in the identified studies (see Table 1), 
from 64 in Parsi to 37207 in Van der Heijden (9, 18). The reliability of the results is greater 
for the studies with greater sample sizes (see Pak and Lim), due to the increased likelihood 
that their conclusions are directly transferrable to a national population (11, 18). None of the 
articles utilised the smart phone application technology for image capture or transfer, which 
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is an area of emerging teledermatology research. This means that these articles have not 
assessed the current technology within the field of teledermatology (21). Two of the 
economic analyses (18%) were conducted on S&FTD services post-implementation (10, 16). 
This post-implementation method of evaluating cost means that researchers had reduced 
ability to randomise effectively and have adequate control populations. This study design, 
although pragmatic, makes the reported cost evaluations less rigorous. Finally, the resources 
identified for cost analysis differed between studies reducing their comparability. Some of the 
differences were driven by their economic perspectives and national funding bodies, and by 
the data collection methods (patient self-reporting costs) (18).  
 
Further research 
Further research is required in the area of S&FTD economic evaluation. Studies should focus 
on applying the most appropriate economic analysis methods,  include a consideration of 
effectiveness measures, and consult the CHEERS checklist when writing to ensure all 
elements are addressed (12). There should also be a focus on emerging technologies such as 
smart phone applications that utilise dermatoscope attachments (teledermoscopy) where 
appropriate. Analysis should be informed primarily by RCTs or where necessary pragmatic 
study designs. Economic analysis models should be designed that include as many relevant 
outcomes and cost factors as possible (this is easily achieved by using a tool like CHEERS) 
and can be applied to screening and diagnosis for standard and high risk populations.  
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Conclusion  
Current evidence suggests that S&FTD can be cost-effective. It appears to be cost-effective 
when it is used as a triage mechanism to reduce FTF appointment requirements. The cost-
effectiveness of S&FTD increases when patients are required to travel further distances to 
access dermatology services. Further economic research is required for the emerging S&FTD 
which uses dermatoscopes in combination with smartphone applications, and around the 
possibility and consequences of patients self-capturing and transmitting images. 
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Figure Legends: 
 
Figure 1 
Title: Article selection process 
Legend: Figure 1 demonstrates the article selection process and lists the exclusion criteria. It 
is modelled according to the PRISMA protocol.  
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Tables: 
Table 1. Study characteristics (columns continued to next page) 
Author/s 
 
Year Country n Analysis Type* 
(**/***) 
 
CHEERS 
quality score 
(out of 24) 
Datta et al. (4) 2015 USA 392 CUA** 
/CMA** 
 
18 
Eminović et al. 
(15) 
2010 Netherlands 631 CMA** 21 
Ferrandiz et al. 
(16) 
2008 Spain 134 CEA** 18 
Lim et al. (11) 2012 New Zealand 300 CMA*** 13 
Livingstone et al. 
(10) 
2015 UK 248 CEA** 
/CMA*** 
7 
Moreno-Ramirez 
et al. (9) 
2009 Spain 2009 CEA** 16 
Morton et al. (17) 2011 Scotland/UK 477 CA*** 18 
Pak et al. (18) 2009 USA 698 CMA** 17 
Parsi et al. (1) 2012 USA 64 CUA** 21 
Van der Heijden 
et al. (8) 
2011 Netherlands 37207 CMA*** 14 
Whited et al. (7) 2003 USA 275 CEA** 15 
*Cost-analysis (CA), cost-minimisation analysis (CMA), cost-effectiveness analysis 
(CEA), cost-utility analysis (CUA) 
**Analysis type as determined by the author 
***Analysis type not stated by author, determined by reviewer 
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Table 1. Study characteristics (columns continued from previous page) 
Cost of S&FTD per 
patient 
S&FTD concluded to be cost 
effective? 
FTF avoided via 
S&FTD screening 
USD$30 saved (VA) 
 
USD$82 saved (societal) 
Equivalent (VA perspective) 
 
Yes (societal perspective) 
Unspecified 
€ 32.50 saved  Equivalent Unspecified 
€ 122.02 saved Yes Unspecified 
NZ$42 saved  Yes  88%  
₤12460 saved 
(total for all participants) 
Yes 41% 
€ 49.59 saved  Yes 50% 
₤1.70 saved  Yes 72% 
USD$32 saved Yes 39% 
USD$261 saved  Yes N/A 
€ 34.94 saved  Yes 74% 
USD$15 extra  Yes Unspecified 
*Cost-analysis (CA), cost-minimisation analysis (CMA), cost-effectiveness analysis 
(CEA), cost-utility analysis (CUA) 
**Analysis type as determined by the author 
***Analysis type not stated by author, determined by reviewer 
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Table 2. Economic analysis characteristics (columns continue on next page) 
Author, Year Analysis 
Type* 
(**/***) 
 
Economic 
evaluation 
informed by**** 
Quality rating 
of informing 
studies ***** 
Outcome 
Datta et al. (4) CUA** 
/CMA** 
 
RCT 1 ▪ Utility was not found to be 
influenced by the intervention, 
therefore analysis was reduced to 
CMA.  
▪ Two perspectives were examined and 
only the savings from a societal 
perspective were found to be 
statistically significant.  
▪ USD$30 saved per patient (VA) 
USD$82 saved per patient (societal) 
Eminović et al. 
(15) 
CMA** RCT 1 ▪ S&FTD has a 0.11 probability of 
being cost effective 
Ferrandiz et al. 
(16) 
CEA** POS 2 ▪ €3.10/patient /day saved for patients 
with no impediments to travel 
▪ €4.87/patient 
/day saved for patients who had 
impediments to travel 
Lim et al. (11) CMA*** RCT 1 ▪ NZ$42 saved per patient  
Livingstone et 
al. (10) 
CEA** 
/CMA*** 
ROS 3 ▪ ₤12460 saved 
(total for all participants) 
Moreno-
Ramirez et al. 
(9) 
CEA** POS 2 ▪ €0.65/patient /day saved 
Morton et al. 
(17) 
CA*** POS 2 ▪ ₤1.70 saved per patient  
Pak et al. (18) CMA** RCT 1 ▪ USD$32 saved per patient 
Parsi et al. (1) CUA** RCT 1 ▪ Mean improvement in QALYs was 
not significant between groups, 
however S&FTD saved 
$539.58/QALY. 
Van der 
Heijden et al. 
(8) 
CMA*** POS 2 ▪ Cost reduction estimated at 18% 
(average weighted costs) 
Whited et al. 
(7) 
CEA** RCT 1 ▪ USD$0.12-0.17/patient/day saved 
*Cost-analysis (CA), cost-minimisation analysis (CMA), cost-effectiveness analysis (CEA), cost-utility 
analysis (CUA) 
**Analysis type as determined by the author 
***Analysis type not stated by author, determined by reviewer 
****Randomised control trial (RCT), Retrospective observational study (ROS), Prospective observational 
study (POS) 
*****Evidence quality rating: 1 (Properly powered and conducted randomized clinical trial; systematic 
review with meta-analysis), 2 (Well-designed controlled trial without randomization; prospective), 
comparative cohort trial, 3 (Case-control studies; retrospective cohort study), 4 (Case series with or without 
intervention; cross-sectional study), 5 (Opinion of respected authorities; case reports) 
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Table 2. Economic analysis characteristics (columns continued from previous page) 
 
 
Perspective Was effectiveness evaluated? Sensitivity testing 
Department of Veterans Affairs, 
USA 
 
& Societal (individual costs only) 
Yes, in terms of QALYs No 
Societal (individual costs only) Yes, in terms of unnecessary 
referrals. Effectiveness was not 
considered jointly alongside cost. 
Yes  
(showed that coat-effectiveness is 
dependent on the travel 
requirements on the patient or 
greater FTF avoided) 
NHS, Spain Yes, in terms of time to initial 
intervention 
No 
NHS, New Zealand  Yes, in terms of time to initial 
intervention and other measures  
No 
NHS, United Kingdom Yes, in terms of referral time. 
Effectiveness was not considered 
jointly alongside cost. 
No 
Unspecified Yes, in terms of time to initial 
intervention 
Yes  
(Showed that S&FTD is still cost 
effective if avoided FTF 
appointments are reduced by a 
further 25%) 
NHS, United Kingdom Yes. Effectiveness was not 
considered jointly alongside cost. 
No 
Department of defence, USA Yes, comparable outcomes 
previously demonstrated and 
described.  
 
No 
Societal (institutional, individual, 
and governmental costs) 
Yes, in terms of QALYs Yes  
(travel time to attend a FTF was 
varied between 30-180min) 
NHS, Netherlands Yes, in terms of prevented 
referrals. Effectiveness was used to 
calculate a weighted change in 
cost.  
No 
Department of Veterans Affairs, 
USA 
Yes, in terms of time to initial 
intervention 
Yes  
(showed that cost-effectiveness is 
dependent on the number of 
appointments avoided) 
*Cost-analysis (CA), cost-minimisation analysis (CMA), cost-effectiveness analysis (CEA), cost-utility 
analysis (CUA) 
**Analysis type as determined by the author 
***Analysis type not stated by author, determined by reviewer 
****Randomised control trial (RCT), Retrospective observational study (ROS), Prospective 
observational study (POS) 
*****Evidence quality rating: 1 (Properly powered and conducted randomized clinical trial; systematic 
review with meta-analysis), 2 (Well-designed controlled trial without randomization; prospective), 
comparative cohort trial, 3 (Case-control studies; retrospective cohort study), 4 (Case series with or 
without intervention; cross-sectional study), 5 (Opinion of respected authorities; case reports) 
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Table 3. Store and forward methodology 
Author, 
Year 
Condition S&F camera S&F transfer 
method 
Image 
captured by 
S&F 
system 
cost taken 
into 
account? 
(Yes/No) 
Datta et al. 
(4) 
Any 
(ambulatory 
skin 
conditions) 
Digital 
camera 
Unspecified Unspecified  No 
Eminović et 
al. (15) 
Unspecified Digital 
camera 
Website 
/Server 
GP Yes 
Ferrandiz et 
al. (16) 
Either non-
melanoma 
skin cancer 
or fast-
growth 
vascular 
tumour 
suitable for 
surgery 
under local 
anaesthesia 
Digital 
camera 
Intranet GP Yes 
Lim et al. 
(11) 
Any (except 
specified 
physical 
area) 
Dermatoscope Website 
/Server  
Melanographer No 
Livingstone 
et al. (10) 
Unspecified Dermatoscope Secure e-mail Trained staff 
member 
Yes 
Moreno-
Ramirez et 
al. (9) 
Suspected 
cancer  
Unspecified  Intranet GP Yes 
Morton et al. 
(17) 
Suspected 
cancer 
Dermatoscope Server Melanographer No 
Pak et al. 
(18) 
Any (except 
emergent or 
complicated 
cases) 
Digital 
camera 
Website/Server Unspecified No 
Parsi et al. 
(1) 
Psoriasis Digital 
camera 
Website/Server Patient Yes 
Van der 
Heijden et 
al. (8) 
Unspecified Digital 
camera 
Website/Server GP No 
Whited et al. 
(7) 
Unspecified Digital 
camera 
Unspecified Unspecified  Yes 
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